Efgartigimod alfa and hyaluronidase (Vyvgart Hytrulo)

Antibody fragment

Approvedregulatory verdict

Evidence outlook

Approved: Generalized Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Featured evidence outside this drug's tracked markets:PET-AON (NCT06453694) · Optic Neuritis · Phase 2 · ungraded

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2/3 (1)
Other / comorbidity
NCT07860021 · Thomas Jefferson University
2026-09-30 – 2028-07-31 · Stiff Person Syndrome
What this study did
Phase 2 (1)
Other / comorbidity
NCT06453694 · Anastasia Vishnevetsky, MD, MPH
2025-08-12 – 2028-06 · Optic Neuritis
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Chronic Inflammatory Demyelinating Polyneuropathy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Efgartigimod Alfa And Hyaluronidase (Vyvgart Hytrulo): this drugApprovedAntibody fragmentFcRnnot yet gradedNo reviewed efficacy summary in this indication
Efgartigimod Alfa (Vyvgart)
Approved(overall)
Antibody fragmentFcRnnot yet gradedNo reviewed efficacy summary in this indication
RiliprubartPhase 3Monoclonal antibodyComplement C1snot yet gradedNo reviewed efficacy summary in this indication
ImeroprubartPhase 2Monoclonal antibodyFcRnnot yet gradedNo reviewed efficacy summary in this indication
TAK-411
—(overall)
Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Efgartigimod alfa and hyaluronidase (Vyvgart Hytrulo) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
June 2027 (1)
Phase 2Optic NeuritisRecruiting
Est. primary completion 2027-06 · NCT06453694 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2/3Stiff Person SyndromeRecruiting
Est. primary completion 2027-12-31 · NCT07860021 · CT.gov ↗
What to watch

See the full readout calendar ↗